Market closed
MacroGenics/$MGNX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MacroGenics
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
Ticker
$MGNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
339
Website
MacroGenics Metrics
BasicAdvanced
$190M
-
-$1.56
2.08
-
Price and volume
Market cap
$190M
Beta
2.08
52-week high
$21.88
52-week low
$2.91
Average daily volume
528K
Financial strength
Current ratio
3.746
Quick ratio
3.526
Long term debt to equity
24.45
Total debt to equity
28.401
Interest coverage (TTM)
-94.03%
Management effectiveness
Return on assets (TTM)
-22.15%
Return on equity (TTM)
-62.17%
Valuation
Price to revenue (TTM)
1.339
Price to book
1.58
Price to tangible book (TTM)
1.58
Price to free cash flow (TTM)
-3.066
Growth
Revenue change (TTM)
16.68%
Earnings per share change (TTM)
-293.99%
3-year revenue growth (CAGR)
6.81%
3-year earnings per share growth (CAGR)
-14.38%
What the Analysts think about MacroGenics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MacroGenics stock.
MacroGenics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MacroGenics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MacroGenics News
AllArticlesVideos
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·2 months ago
MacroGenics to Participate in Upcoming Investor Conference
GlobeNewsWire·2 months ago
MacroGenics to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MacroGenics stock?
MacroGenics (MGNX) has a market cap of $190M as of January 31, 2025.
What is the P/E ratio for MacroGenics stock?
The price to earnings (P/E) ratio for MacroGenics (MGNX) stock is 0 as of January 31, 2025.
Does MacroGenics stock pay dividends?
No, MacroGenics (MGNX) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next MacroGenics dividend payment date?
MacroGenics (MGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for MacroGenics?
MacroGenics (MGNX) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.